Aardvark Therapeutics, Inc.
AARD$275M
Micro CapNASDAQBiotechnology🇺🇸North America33 employees
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Mar 15, 2026
5wData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
1 upcoming, 0 past
⭐Phase 3Next
ARD-101 Phase 3 Results Expected
March 2026~ARD-10190
Primary completion for ARD-101 trial (NCT06828861) in Hyperphagia
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
ARD-101 | Phase 3 | Hyperphagia | - |
Low Dose ARD-501 | Phase 2 | Autism Spectrum Disorder | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
AARD News